Drug intelligence / Profile preview

cannabidiol + β-caryophyllene

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Topical, Sublingual
01

Overview

Cannabidiol + β-caryophyllene is a combination of two naturally occurring compounds found in the cannabis plant—cannabidiol (CBD), a non-psychoactive cannabinoid, and β-caryophyllene (BCP), a dietary sesquiterpene that acts as a selective agonist at the cannabinoid receptor type 2 (CB2). This combination has been shown in preclinical studies to produce synergistic analgesic and anti-inflammatory effects greater than either compound alone. The mechanism involves modulation of inflammatory pathways and interaction with both CB1 and CB2 receptors. Notably, this synergy occurs without the psychoactive side effects typically associated with cannabinoid receptor type 1 activation. The combination is being investigated primarily for pain management—including neuropathic pain—and inflammation-related conditions[1][2][3][4][5][7].

Other names
CBD + BCPcannabidiol and beta-caryophylleneCBD/BCP
02

Targets

CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on cannabidiol + β-caryophyllene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabidiol + β-caryophyllene.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call